ALLG MM26/D1: Novel Combinations for Orphan Myeloma: The NORM Platform study: Treatment Specific Appendix: Selinexor, Pomalidomide, Dexamethasone (SPd)

Australasian Leukaemia & Lymphoma Group0 个研究点目标入组 140 人开始时间: 2022年10月11日最近更新: 2024年3月4日

适应症

试验速览

暂无简介。

•Eligibility criteria specific to Treatment Specific Appendix - Selinexor, Pomalidomide, Dexamethasone (SPd) include:
•1.Previous bortezomib therapy and either: failure to achieve at least a partial response (PR) during treatment OR progressive disease (PD) during treatment or within 6 months of discontinuing treatment OR contraindication or experienced an intolerance to treatment with bortezomib AND
•2.Previous lenalidomide therapy and either: treatment failure with lenalidomide, as confirmed by progressive disease during treatment within 6 months of discontinuing lenalidomide OR a contraindication or intolerance to treatment with lenalidomide.
•3.Must agree to contraceptive requirements

•See ALLG MM26/NORM: Novel Combinations for Orphan Myeloma: The NORM platform study Master Protocol for eligibility criteria relevant to all domain protocols.
•Exclusion criteria specific to Treatment Specific Appendix - Selinexor, Pomalidomide, Dexamethasone (SPd) include:
•1.Previous treatment with pomalidomide or Selinexor
•2.Contraindication to pomalidomide, Selinexor or dexamethasone
•3.Active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of trial treatments.

发起方